| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2024-019 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 包头东宝生物技术股份有限公司 关于使用部分暂时闲置募集资金及自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司(以下简称"公司")于2024年4月22日召开第八届 董事会第二十次会议、第八届监事会第十九次会议，审议通过了《关于使用部分暂 时闲置募集资金及自有资金进行现金管理的议案》，同意公司在确保不影响募集资 金投资项目建设、不改变募集资金使用用途、不影响公司正常生产经营以及确保资 金安全的前提下，使用额度不超过35,000万元(含本数)的部分暂时闲置募集资金和不 超过30,000万元(含本数)自有资金(合计不超过65,000万元，含本数)进行现金管理， 期限自第八届董事会第二十次会议通过之日起12个月内有效，在前述额度和期限范 围内，资金可以循环滚动使用。本事项在董事会审议权限范围内，无需提交公司股 东大会审议。公司董事 ...

包头东宝生物技术股份有限公司 独立董事提名人声明与承诺 (王京) 提名人包头东宝生物技术股份有限公司董事会现就提名王京为包头东宝 生物技术股份有限公司第九届董事会独立董事候选人发表公开声明。被提名人 已书面同意作为包头东宝生物技术股份有限公司第九届董事会独立董事候选 人（参见该独立董事候选人声明）。本次提名是在充分了解被提名人职业、学 历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况后作 出的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性文 件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求，具 体声明并承诺如下事项： 一、被提名人已经通过包头东宝生物技术股份有限公司第八届董事会独立 董事专门会议资格审查，提名人与被提名人不存在利害关系或者其他可能影响 独立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不 得担任公司董事的情形。 ☑ 是 □ 否 （如有）。 ☑ 是 □ 否 如否，请详细说明：_____________________ ...

包头东宝生物技术股份有限公司 | 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2024-012 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 第八届监事会第十九次会议决议公告 本公司及监事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、包头东宝生物技术股份有限公司(以下简称"公司")第八届监事会第十 九次会议通知于 2024 年 4 月 12 日以直接送达或电子邮件等方式通知了全体监事。 2、会议召开时间、地点及方式：现场与通讯方式结合。现场会议于 2024 年 4 月 22 日(星期一)下午 13:30 在包头稀土高新区包头东宝生物技术股份有限公 司会议室召开。 3、会议出席人员：本次会议应出席监事 3 名，实际出席监事 3 名(其中通讯 出席监事 1 名、现场出席监事 2 名)，监事会主席周兴先生以通讯方式出席会议， 监事于建华先生、杜学文先生出席现场会议。第九届监事会非职工代表监事候选 人孙红喜女士、王珺女士以通讯方式出席会议。 4、本次会议由监事会主席周兴先生主持 ...

招商证券股份有限公司 关于包头东宝生物技术股份有限公司 2023 年度跟踪报告 | 公司及股东承诺事项 | 是否 | 未履行承诺的原因及解 | | --- | --- | --- | | | 履行承诺 | 决措施 | | 刚、郝海青关于公司填补回报措施能够得到 | | | | 切实履行作出的承诺 | | | | 6.公司关于对募集资金到位后即期回报被摊 | 是 | 不适用 | | 薄采取措施的承诺 | | | | 7.海南百纳盛远科技有限公司和王军关于同 | 是 | 不适用 | | 业竞争、关联交易、资金占用方面的承诺 | | | | 8.杭州群利明胶化工有限公司、江萍、江任飞 关于同业竞争、关联交易、资金占用方面的 | 是 | 不适用 | | 承诺 | | | | 9.海南百纳盛远科技有限公司和王军关于公 | 是 | 不适用 | | 司员工公积金问题的承诺 | | | | 10.控股股东青岛国恩科技股份有限公司，实 际控制人王爱国、徐波对公司填补回报措施 | 是 | 不适用 | | 能够得到切实履行所做出的承诺 | | | | 11.董事及高级管理人员王爱国、刘芳、王富 荣、刘燕、高德步、任斌、额尔敦陶克涛 ...

第八届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 | 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2024-011 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 包头东宝生物技术股份有限公司 1、包头东宝生物技术股份有限公司(以下简称"公司")第八届董事会第二 十次会议通知于 2024 年 4 月 12 日以直接送达或电子邮件等方式通知了全体董事、 监事、高级管理人员。 2、会议召开时间、地点及方式：现场与通讯方式结合。现场会议于 2024 年 4 月 22 日(星期一)上午 10:00 在包头稀土高新区包头东宝生物技术股份有限公 司会议室召开。 3、会议出席人员：本次会议应出席董事 7 名，实际出席董事 7 名(其中，董 事长王爱国先生、董事刘燕女士以通讯方式出席会议，董事刘芳先生、王富荣先 生、独立董事高德步先生、任斌先生、额尔敦陶克涛先生现场出席会议)。第九 届董事会独立董事候选人王京先生通讯出席会议。 6、本次会议的召集、召 ...

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2024-023 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 包头东宝生物技术股份有限公司 关于董事会、监事会提前换届选举的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司（以下简称"公司"）第八届董事会、监事会 任期将于2024年9月届满，现根据公司业务发展及生产经营管理的实际需要，拟对董 事会、监事会进行提前换届选举，根据《中华人民共和国公司法》、《上市公司独 立董事管理办法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所 上市公司自律监管指引第2号—创业板上市公司规范运作》等相关法律法规、规范性 文件及《公司章程》的有关规定，公司开展了董事会、监事会换届工作，现将换届 工作具体情况公告如下： 一、董事会换届工作情况 公司于2024年04月22日召开第八届董事会第二十次会议，逐项审议通过了《关 于董事会提前换届选举暨提名第九届董事会非独立董事候选人的议案》、《关于董 事会提前换届选举暨提名 ...

包头东宝生物技术股份有限公司 董事会关于独立董事独立性情况的专项意见 包头东宝生物技术股份有限公司（以下简称"公司"）董事会根据《上市公 司独立董事管理办法》、《深圳证券交易所创业板股票上市规则》、《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等要求，对 公司独立董事的独立性情况进行评估并出具如下专项意见： 经核查，公司独立董事高德步先生、任斌先生、额尔敦陶克涛先生均未在公 司担任独立董事以外的任何职务，也未在公司主要股东担任任何职务，与公司及 公司主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系， 不存在其他影响独立董事独立性的情况。公司独立董事符合《上市公司独立董事 管理办法》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等法律法规、规范性文件和公司《独立董事工作制度》中关于独立 董事独立性的相关要求。 包头东宝生物技术股份有限公司 董事会 2024 年 4 月 24 日 ...

Dividend and Financial Performance - The company plans to distribute a cash dividend of 0.22 RMB per 10 shares (including tax) to all shareholders[4]. - The company's operating revenue for 2023 was ¥974,512,217.68, representing a 3.30% increase compared to ¥943,396,998.69 in 2022[24]. - Net profit attributable to shareholders for 2023 was ¥119,885,372.42, a 9.55% increase from ¥109,437,321.14 in 2022[24]. - Basic earnings per share for 2023 were ¥0.2020, reflecting a 9.54% increase from ¥0.1844 in 2022[24]. - The weighted average return on equity for 2023 was 7.46%, slightly up from 7.42% in 2022[24]. - The total assets at the end of 2023 reached ¥2,742,011,238.13, an 18.80% increase from ¥2,308,113,622.60 at the end of 2022[24]. - The company achieved operating revenue of ¥974,512,217.68, a year-on-year increase of 3.30%, and a total profit of ¥144,492,588.73, up 9.76% from the previous year[73]. - The company reported a gross margin of 45%, indicating strong operational efficiency[67]. - The total assets of the company increased by 12% to 2 billion RMB, reflecting solid financial health[67]. Revenue Growth and Market Expansion - The company reported a significant increase in revenue, with a year-on-year growth of 15% in the latest fiscal year[19]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% year-over-year growth[67]. - User data showed a 15% increase in active users, reaching 3 million by the end of the year[67]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[67]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on innovative healthcare solutions[67]. - Market expansion plans include entering three new international markets, aiming for a 10% market share within the first year[67]. - The company is actively expanding into the medical, pharmaceutical, aesthetic, and nutritional health food sectors, leveraging its listing platform and brand advantages for multi-dimensional marketing[70]. Production Capacity and Product Development - The company is expanding its production capacity, aiming to increase gelatin production from 3,500 tons to 7,000 tons annually[19]. - The company aims to develop high-value-added collagen products to meet market demand and maintain its leading position in the natural collagen industry[34]. - The company is focusing on the development of ultra-low endotoxin gelatin for regenerative medicine applications, targeting medical devices and pharmaceutical products[37]. - The company has an annual production capacity of 13,500 tons for gelatin and 39 billion capsules, with plans to expand to nearly 70 billion capsules after the completion of the new production project[49]. - The company is actively expanding its production capabilities, with plans to achieve an annual output of 300 billion capsules in the near future, positioning itself as a leading manufacturer in the industry[60]. - The company is focusing on the development of high-end markets, with its blood plasma gelatin included in the national guidelines for upgraded and innovative consumer products, enhancing its market presence[77]. Research and Development - The company is investing heavily in R&D, allocating 10% of its revenue to develop new technologies and improve existing products[67]. - The company has obtained a total of 50 patents, including 28 Chinese invention patents and 1 US invention patent, with 6 new patents granted during the reporting period[65]. - The company has published a total of 45 papers, with 2 new papers published during the reporting period[65]. - The company is focusing on technological innovation and has accelerated the development of high-value collagen projects, including applications in low-fat cream technology and hair care[85]. - The company has established a collaborative research project with Jiangnan University to explore collagen protein applications in the textile industry, which has received funding support[86]. - The company is developing a low-endotoxin gelatin preparation process aimed at enhancing product value and achieving specific technical indicators[99]. Quality Management and Compliance - The company is committed to maintaining compliance with international quality standards, including FDA and ISO certifications[19]. - The company has established a comprehensive quality management system, certified by multiple international standards, ensuring product safety and quality stability[62]. - The company has achieved various quality management certifications, including NSF-GMP and FSSC22000, enhancing its product quality assurance[85]. - The company emphasizes a centralized procurement model to ensure quality control from the sourcing of raw materials to production[56]. Strategic Acquisitions and Partnerships - The company is considering strategic acquisitions to bolster its market position and enhance its product offerings[19]. - The company has established partnerships with various research institutions to advance its technological capabilities[19]. - The company has established stable partnerships with major pharmaceutical companies, ensuring a solid foundation for future business growth[78]. - The company aims to capture more market share in both B2B and B2C sectors due to stricter regulations and accelerated industry consolidation[47]. Financial Management and Investments - The company successfully issued convertible bonds, raising ¥455 million to support business expansion and enhance its health industry layout[75]. - The total investment amount for the reporting period was CNY 195,161,401.38, representing a 25.18% increase compared to the previous year's investment of CNY 155,905,672.96[114]. - The company has committed a total investment of RMB 86.23 million for various projects, with RMB 47.59 million cumulatively invested by the end of the reporting period[126]. - The company has not engaged in any securities or derivative investments during the reporting period[118][119]. - The company has reported a net financial income of RMB 5.54 million from investment returns and bank interest after deducting fees as of December 31, 2023[123]. Governance and Management - The company held 3 shareholder meetings during the reporting period, all convened by the board of directors and presided over by the chairman[160]. - The board of directors consists of 7 members, including 3 independent directors, and has established various committees to ensure compliance with regulations[162]. - The company has established a performance evaluation and incentive system for its executives, ensuring transparency and compliance with legal standards[165]. - The company maintains independent operations from its controlling shareholder, with no instances of fund occupation or guarantees provided to the controlling shareholder[161][168]. - The company has a complete and independent asset structure, with all assets under the control of the listed company[168]. Market Trends and Consumer Insights - The global retail market for nutritional health products reached $182.67 billion in 2023, with an expected CAGR of 5.7% over the next five years, projected to reach $241.1 billion by 2028[38]. - In 2023, the per capita healthcare expenditure in China was ¥2,460, accounting for 9.2% of total consumer spending, showing a year-on-year increase[39]. - The domestic beauty market size was ¥390.3 billion in 2021, with a CAGR of 11.51% from 2007 to 2021, expected to reach ¥577.9 billion by 2026[40]. - The anti-aging skincare market in China grew from ¥35.6 billion in 2016 to ¥82 billion in 2021, with a CAGR of 18.1%, projected to reach ¥153.2 billion by 2026[40]. Challenges and Risks - The company has outlined potential risks in its future operations and has strategies in place to mitigate these risks[4]. - The company is facing risks related to management as it scales operations, necessitating improved operational capabilities and management systems[150]. - The company is addressing intensified market competition by focusing on product innovation and customized technical services to enhance core competitiveness[151].

包头东宝生物技术股份有限公司 2023 年度 募集资金年度存放与使用情况鉴证报告 | 索引 | | 页码 | | --- | --- | --- | | 鉴证报告 | | 1-2 | | 2023 | 年度募集资金年度存放与使用情况的专项报告 | 1-16 | | | | 9/F, Block A, Fu Hua Mansion, | | --- | --- | --- | | 1G | No.8 Chaoyangmen Beidajie, ShineWing Dongcheng District, Beijing, 传真: | +86 (010) 6554 7190 | | 11 | sentified nublic accessuntante (400007 D D China Comments of | 1 | 募集资金年度存放与使用情况鉴证报告 XYZH/2024JNAA1F0012 包头东宝生物技术股份有限公司 包头东宝生物技术股份有限公司全体股东： 我们对后附的包头东宝生物技术股份有限公司(以下简称东宝生物公司)2023 年度 募集资金年度存放与使用情况的专项报告（以下简称募集资金年度存放与使用情 ...

包头东宝生物技术股份有限公司 2024 年第一季度报告 证券代码：300239 证券简称：东宝生物 公告编号：2024-022 包头东宝生物技术股份有限公司 2024 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 包头东宝生物技术股份有限公司 2024 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | （%） | | | 营业收入（元） | 241,778,598.22 | 261,319,537.08 | | - ...